Genetic sequencing firm Illumina, Inc. has agreed to pay $325m to rival BGI, putting an end to multiple intellectual property suits that had been pending between the two companies. The resolution was announced in a 14 July filing with the US Securities and Exchange Commission.
The settlement resolves at least eight separate US lawsuits, including four underway in US district courts and four being appealed in the Court of Appeals for the Federal Circuit
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?